Search
Now showing items 1-7 of 7
Cross-clade CD8(+) T-cell responses with a preference for the predominant circulating clade
(University of Nairobi, 2005-11)
Human immunodeficiency virus (HIV) genetic diversity is a major impediment to the design of a successful vaccine. Even if an HIV vaccine is proven effective, it remains to be seen whether this protection will extend to ...
Construction of an infectious HIV type 1 molecular clone from an African patient with a subtype D/C Recombinant Virus.
(2004)
The majority of HIV-1 infections worldwide occur in Africa, where subtype B viruses are rare and intersubtype recombinants are common. Pathogenesis and vaccine studies need to focus on viruses derived from African patients, ...
IL-7Ralpha expression on DC4+ T lymphocytes decreases with HIV disease progression and inversely correlates with immune activation
(University of nairobi, 2006)
Many factors can influence the rate of HIV disease progression, including those that maintain T cell homeostasis. One key homeostatic regulator is the IL-7 receptor (IL-7R). Previous studies have shown IL-7R expression ...
Cd4+ T Cell Responses In Hiv-exposed Seronegative Women Are Qualitatively Distinct From Those In Hiv-infected Women
(University of Nairobi, 2005-01)
The immune response of human immunodeficiency virus (HIV)-exposed seronegative (ESN) women may be qualitatively different from that in those infected with HIV (HIV(+)). In a cohort of female commercial sex workers in ...
Elevated T Cell Counts And Rantes Expression In The Genital Mucosa Of Hiv-1-resistant Kenyan Commercial Sex Workers.
(University of Nairobi, 2005-09)
The initial site of exposure to human immunodeficiency virus (HIV)-1 during heterosexual transmission occurs in the genital tract. Although the majority of immunological studies have focused on the immune response to HIV-1 ...
Cross-clade CD8(+) T-cell responses with a preference for the predominant circulating clade.
(University of Nairobi, 2005)
Human immunodeficiency virus (HIV) genetic diversity is a major impediment to the design of a successful vaccine. Even if an HIV vaccine is proven effective, it remains to be seen whether this protection will extend to ...